Literature DB >> 23334208

Clinical targeting of the TNF and TNFR superfamilies.

Michael Croft1, Chris A Benedict, Carl F Ware.   

Abstract

Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional members of the TNF superfamily of structurally related cytokines. Many of these TNF-related cytokines or their cognate receptors are now in preclinical or clinical development as possible targets for modulating inflammatory diseases and cancer as well as other indications. This Review focuses on the biologics that are currently in clinical trials for immune-related diseases and other syndromes, discusses the successes and failures to date as well as the expanding therapeutic potential of modulating the activity of this superfamily of molecules.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23334208      PMCID： PMC3625401          DOI： 10.1038/nrd3930

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  214 in total

1.  Anti-NGF painkillers back on track?

Authors:  David Holmes
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694

Review 2.  Insights into TL1A and IBD pathogenesis.

Authors:  David Q Shih; Kathrin S Michelsen; Robert J Barrett; Eva Biener-Ramanujan; Rivkah Gonsky; Xiaolan Zhang; Stephan R Targan
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 3.  Anti-GITR antibodies--potential clinical applications for tumor immunotherapy.

Authors:  David A Schaer; Adam D Cohen; Jedd D Wolchok
Journal:  Curr Opin Investig Drugs       Date:  2010-12

Review 4.  Therapeutic targeting of CD95 and the TRAIL death receptors.

Authors:  Jeannette Gerspach; Klaus Pfizenmaier; Harald Wajant
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-09       Impact factor: 4.169

5.  Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.

Authors:  A Deodhar; R K Dore; D Mandel; J Schechtman; W Shergy; R Trapp; P A Ory; C G Peterfy; T Fuerst; H Wang; L Zhou; W Tsuji; R Newmark
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

6.  An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Authors:  Nicholas S Wilson; Becky Yang; Annie Yang; Stefanie Loeser; Scot Marsters; David Lawrence; Yun Li; Robert Pitti; Klara Totpal; Sharon Yee; Sarajane Ross; Jean-Michel Vernes; Yanmei Lu; Cam Adams; Rienk Offringa; Bob Kelley; Sarah Hymowitz; Dylan Daniel; Gloria Meng; Avi Ashkenazi
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

Review 7.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

8.  Combining radiotherapy with APO010 in cancer treatment.

Authors:  Inge Verbrugge; Esther H J Wissink; Rogier W Rooswinkel; Johan Jongsma; Nicola Beltraminelli; Marc Dupuis; Jannie Borst; Marcel Verheij
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 9.  Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.

Authors:  Norma Lynn Fox; Robin Humphreys; Troy A Luster; Jerry Klein; Gilles Gallant
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

10.  Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease.

Authors:  Philippe Maerten; Karel Geboes; Gert De Hertogh; Chong Shen; Pascal Cadot; Dominique M A Bullens; Gert Van Assche; Freddy Penninckx; Paul Rutgeerts; Jan L Ceuppens
Journal:  Clin Immunol       Date:  2004-09       Impact factor: 3.969
View more
  153 in total

1.  Basophil-associated OX40 ligand participates in the initiation of Th2 responses during airway inflammation.

Authors:  Caixia Di; Xiaoliang Lin; Yanjie Zhang; Wenwei Zhong; Yufan Yuan; Tong Zhou; Junling Liu; Zhenwei Xia
Journal:  J Biol Chem       Date:  2015-04-03       Impact factor: 5.157

2.  T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways.

Authors:  Kohei Hosokawa; Sachiko Kajigaya; Keyvan Keyvanfar; Wangmin Qiao; Yanling Xie; Danielle M Townsley; Xingmin Feng; Neal S Young
Journal:  J Immunol       Date:  2017-06-19       Impact factor: 5.422

Review 3.  Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases.

Authors:  Medya M Shikhagaie; Kristine Germar; Suzanne M Bal; Xavier Romero Ros; Hergen Spits
Journal:  Nat Rev Rheumatol       Date:  2017-02-02       Impact factor: 20.543

Review 4.  [Immunomodulation as innovative therapy for head and neck tumors : Current developments].

Authors:  P J Schuler; J C Doescher; S Laban; T K Hoffmann
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

Review 5.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

6.  Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Authors:  Paurvi Shinde; Wenhai Liu; Antoine Ménoret; Andrew D Luster; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2017-04-21       Impact factor: 4.962

7.  A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo.

Authors:  Tsung-Chieh Shih; Ruiwu Liu; Gabriel Fung; Gaurav Bhardwaj; Paramita M Ghosh; Kit S Lam
Journal:  Mol Cancer Ther       Date:  2017-04-10       Impact factor: 6.261

Review 8.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

9.  TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB.

Authors:  Viraga Haridas; Polidy Pean; Luke D Jasenosky; Yoann Madec; Didier Laureillard; Thim Sok; Sun Sath; Laurence Borand; Olivier Marcy; Sarin Chan; Erdyni Tsitsikov; Jean-François Delfraissy; François-Xavier Blanc; Anne E Goldfeld
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

Review 10.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.